Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 496 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Buprenorphine Clear all
Terminated Phase 2 Interventional

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

NCT02161354
View directory record Official record
Conditions
Dental Pain
Interventions
NTC-510 capsules, Placebo Capsules, NTC-510A Capsules
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2

NCT00015041
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Evaluation of Liquid vs. Tablet Buprenorphine - 6

NCT00000341
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

NCT02537574
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Oceanside, California • Orange, California • Lauderhill, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 22, 2026, 5:04 PM EDT
Recruiting Phase 2 Interventional

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

NCT06067737
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

NCT04677114
View directory record Official record
Conditions
Drug Use, Opioid-use Disorder
Interventions
Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment
Drug
Lead sponsor
Laura Fanucchi
Other
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Effects of Buprenorphine and Naloxone in Opiate Addicts - 4

NCT00000355
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 5:04 PM EDT
Recruiting Phase 4 Interventional

Buprenorphine, Clonidine, and Dexamethasone on Duration of Brachial Plexus Blocks for Upper Extremity Surgery

NCT05824832
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Interscalene block with the addition of buprenorphine, clonidine, dexamethasone, Interscalene block with buprenorphine alone
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 22, 2026, 5:04 PM EDT
Recruiting Phase 3 Interventional

Standard Versus High Dose ED-Initiated Buprenorphine Induction

NCT06494904
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Oakland, California • San Leandro, California • Portland, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Study of Computer-Based Treatment for Drug Dependence

NCT01315184
View directory record Official record
Conditions
Opioid-Related Disorders, Heroin Dependence
Interventions
Recovery Line Support System
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 22, 2026, 5:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

NCT01260675
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine HCl/Naloxone HCl
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

NCT01259102
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Buprenorphine Dose Alteration Study - 1

NCT00000219
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
19 Years to 41 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 22, 2026, 5:04 PM EDT
Completed No phase listed Observational Results available

Evaluation of Long-term Buprenorphine Plasma Exposure

NCT03752528
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Blood sample collection, Urine sample collection
Diagnostic Test
Lead sponsor
Indivior Inc.
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
11
States / cities
Hamilton, Alabama • Tampa, Florida • Prairie Village, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion

NCT05976646
View directory record Official record
Conditions
Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder
Interventions
Placebo, Auvelity
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Testosterone Replacement for Male Opioid Agonist Maintained Patients

NCT01873989
View directory record Official record
Conditions
Chronic Pain, Opioid Addiction, Symptomatic Hypogonadism
Interventions
Testosterone replacement, Waitlist control
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buprenorphine/Raltegravir Pharmacokinetic Interaction Study

NCT00858962
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
Raltegravir
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 22, 2026, 5:04 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation

NCT03420313
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone sublingual tablets
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment for Opioid Dependent Offenders

NCT01082679
View directory record Official record
Conditions
Opioid Dependence
Interventions
Methadone, buprenorphine (Suboxone)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

NCT02559973
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, SUBOXONE Sublingual Film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Not applicable Interventional Results available

Trial of Adherence App for Buprenorphine Treatment (TAAB) Study

NCT03779997
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Video-based DOT Application
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 22, 2026, 5:04 PM EDT
Recruiting Phase 4 Interventional

BUprenorphine Versus Morphine for Postcesarean Analgesia (BUMP)

NCT07786012
View directory record Official record
Conditions
Cesarean Delivery
Interventions
buprenorphine, morphine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
19 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:04 PM EDT
Not listed Not applicable Interventional

Are Superficial Parasternal Intercostal Plane (SPIP) Blocks With Bupivacaine and With or Without Adjuvants Helpful for Post-operative Pain After Coronary Artery Bypass Grafting?

NCT05003765
View directory record Official record
Conditions
Post-operative Pain Management
Interventions
Bupivacaine 0.25% Injectable Solution, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 22, 2026, 5:04 PM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Loading in the Emergency Department

NCT04283500
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine Naloxone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 22, 2026, 5:04 PM EDT